Edwards Lifesciences (EW) Total Liabilities (2009 - 2026)

Edwards Lifesciences has reported Total Liabilities for 18 years, with the latest figure at $3.1 billion in Q2 2026.

• On a quarterly basis, Total Liabilities rose 9.02% year-over-year to $3.1 billion in Q2 2026; TTM through Jun 2026 was $3.1 billion, a 9.02% increase from a year earlier, with the FY2025 full-year figure at $3.4 billion, up 12.27% from the prior year.
• Total Liabilities was $3.1 billion for Q2 2026 at Edwards Lifesciences, up from $3.0 billion in the prior quarter.
• The five-year high for Total Liabilities was $3.4 billion in Q3 2024, with the low at $2.4 billion in Q3 2022.
• Average Total Liabilities over 5 years is $2.8 billion, with a median of $2.6 billion recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Total Liabilities advanced 27.09% in 2024, then declined 8.71% in 2025.
• Over 5 years, Total Liabilities stood at $2.5 billion in 2022, then gained by 6.36% to $2.6 billion in 2023, then gained by 13.19% to $3.0 billion in 2024, then advanced by 12.27% to $3.4 billion in 2025, then retreated by 6.47% to $3.1 billion in 2026.
• The last three Total Liabilities figures came in at $3.1 billion (Q2 2026), $3.0 billion (Q1 2026), and $3.4 billion (Q4 2025), per Business Quant data.